News

News & Events

Stay informed with Atriva Therapeutics

Atriva Therapeutics strengthens advisory board with Piet Wigerinck
Atriva Therapeutics to take part in upcoming scientific and industry conferences
Atriva Therapeutics’ lead candidate Zapnometinib shows substantial efficacy against SARS-CoV-2
Atriva Therapeutics to take part in upcoming scientific and industry conferences
Spahn/Karliczek: Weiterer Schub zur Entwicklung und Herstellung von versorgungsnahen Arzneimitteln gegen COVID-19
Förderung von Arzneimittelkandidaten gegen COVID-19 aus der Fördermaßnahme „Klinische Entwicklung von versorgungsnahen …
Atriva Therapeutics to take part in upcoming scientific and industry conferences
Atriva Therapeutics to take part in upcoming scientific and industry conferences

News Overview

Title
Atriva Therapeutics strengthens advisory board with Piet WigerinckAtriva Therapeutics to take part in upcoming scientific and industry conferences2021-12-02Press Releasepublish
Atriva Therapeutics’ lead candidate Zapnometinib shows substantial efficacy against SARS-CoV-2Atriva Therapeutics to take part in upcoming scientific and industry conferences2021-11-09Press Releasepublish
Spahn/Karliczek: Weiterer Schub zur Entwicklung und Herstellung von versorgungsnahen Arzneimitteln gegen COVID-19Förderung von Arzneimittelkandidaten gegen COVID-19 aus der Fördermaßnahme „Klinische Entwicklung von versorgungsnahen COVID-19-Arzneimitteln und deren Herstellungskapazitäten“ von BMG und BMBF.2021-09-06Media Coveragepublish
Atriva Therapeutics to take part in upcoming scientific and industry conferencesAtriva Therapeutics to take part in upcoming scientific and industry conferences2021-08-31Eventspublish
Atriva Therapeutics kann dank Fördermitteln COVID-19-Medikament schneller entwickelnDas biopharmazeutische Unternehmen Atriva Therapeutics GmbH, ein Vorreiter bei der Entwicklung von Therapien zur Behandlung von viralen Infektionen, hat sich Fördermittel des Bundes gesichert.2021-04-21Press Releasepublish
Atriva Therapeutics to Speed up Development of COVID-19 Drug with Federal FundingAtriva Therapeutics GmbH, a company that is pioneering the development of therapies for the treatment of viral infections, has secured up to €11.4 million in federal funding.2021-04-21Press Releasepublish
Atriva Therapeutics Doses First Patient in Phase II RESPIRE trial in COVID-19Atriva Therapeutics GmbH, a biopharmaceutical company that is pioneering the development of host-targeting antiviral therapies, announced today that the first patient was enrolled in its Phase II RESPIRE1 trial in COVID-19.2021-04-13Press Releasepublish
Atriva Therapeutics Announces Changes to Management in COVID-19Atriva Therapeutics GmbH, a biopharmaceutical company that is pioneering the development of host-targeting antiviral therapies, today announced two changes to its management team.2021-04-13Press Releasepublish
NDR Visite: Corona-Forschung: neue Medikamente gegen das Virus?t suchen Forschende nach Medikamenten, die im Falle einer Corona-Infektion die Vermehrung des Virus stoppen und schwere Covid-Erkrankungen verhindern. Eine Möglichkeit: sogenannte Kinasehemmer.2021-03-02Media Coveragepublish
Tagesschau: Woran die Pharmabrance forscht: Schwierige Suche nach Covid-MedikamentBislang verläuft die Suche nach wirksamen Medikamenten gegen Covid-19 eher schleppend - nur wenige Mittel sind schon zugelassen. Doch das könnte sich bald ändern, glauben Experten. Von Notker Blechner, tagesschau.de2021-01-25Media Coveragepublish
BR Bayern 2: Corona-Medikamente: Wirkstoff in der zweiten TestphaseDer Vorstandschef der Biotechnologie-Firma Atriva Therapeutics GmbH, Rainer Lichtenberger, fordert die Bundesregierung auf, auch die Medikamentenforschung gegen Corona zu fördern. 2021-01-22Media Coveragepublish
Atriva Therapeutics Announces Changes to Advisory BoardAtriva Therapeutics GmbH, a biopharmaceutical company pioneering the development of host-targeting antiviral therapies, today announced changes to its Advisory Board.2021-01-20Press Releasepublish
Atriva Therapeutics obtains approval from German authorities for Phase II trial in COVID-19 patients, led by Charité Clinic in BerlinAtriva Therapeutics GmbH, a biopharmaceutical company pioneering the development of host-targeting antiviral therapies, announced today approval from the German Federal Institute for Drugs and Medical Devices (Bundesinstitut für Arzneimittel und Medizinprodukte, BfArM) to initiate a pivotal Phase II clinical study with ATR-002 to treat hospitalized patients with moderate to severe COVID-19.2021-01-05Press Releasepublish
Initiative BEAT-COV fordert Unterstützung für Entwicklung und Produktion neuer, innovativer COVID-19-Medikamente„Wir können lebenswichtige Medikamente zur Behandlung von COVID-19-Patienten zur Verfügung stellen, aber wir benötigen signifikante Unterstützung bei der Finanzierung der Entwicklungs- und Produktionskosten – jetzt!“ 2020-12-02Press Releasepublish
Germany: EIB backs Atriva Therapeutics with €24 million for the development of a potential COVID-19 treatmentThe European Investment Bank (EIB) and Atriva Therapeutics GmbH, a biopharmaceutical company pioneering the development of host-targeting antiviral therapies, concluded a €24 million financing agreement today to facilitate the company’s development and clinical testing of a novel therapy treating severe respiratory infections with RNA viruses.2020-10-20Press Releasepublish
Atriva announces closing of € 8.6 million ($ 10.2 million) oversubscribed convertible loanAtriva Therapeutics GmbH, a biopharmaceutical company pioneering the development of host-targeting antiviral therapies, today announced the closing of a € 8.6 million ($ 10.2 million) convertible loan led by Meneldor B.V. and High-Tech Gründerfonds (HTGF), and joined by existing shareholders and new German and international investors.2020-08-11Press Releasepublish
Publication in PNAS unveils molecular pathway required for influenza virus replication with large potential as an antiviral drug targetAtriva Therapeutics GmbH, a biopharmaceutical company pioneering the development of host-targeting antiviral therapies, today announced the publication of in vitro results by Atriva Co-founder Prof. Stephan Ludwig.2020-06-30Press Releasepublish
Atriva Therapeutics to Develop ATR-002 for Treatment of Patients with COVID-19 in Phase II StudyAtriva Therapeutics GmbH, a biopharmaceutical company pioneering the development of host-targeting antiviral therapies, today announced a clinical strategy to treat patients with moderate to severe COVID-19 who require hospitalization. 2020-05-28Press Releasepublish
Major conferences in San FranciscoAtriva Therapeutics GmbH, a clinical stage biopharmaceutical company pioneering the development of host-targeting antiviral therapies, announces its participation in three upcoming conferences in San Francisco, CA, USA, in January. 2020-01-08Eventspublish
Atriva Therapeutics Reports Results of ATR-002 Phase I Clinical TrialAtriva Therapeutics GmbH, a biopharma­ceutical company pioneering the development of host-targeting antiviral therapies, today announced the successful conclusion and top-line results of its Phase I clinical trial for its lead drug candidate ATR-002. 2019-11-08Press Releasepublish
Atriva Therapeutics to present at the BIO-Europe in HamburgAtriva Therapeutics GmbH, a biopharma­ceutical company pioneering the development of host-targeting antiviral therapies, will present at the upcoming 25th Annual International Partnering Conference BIO-Europe®.2019-10-31Eventspublish
Atriva Therapeutics takes part in four conferences in the upcoming monthsAtriva Therapeutics takes part in four conferences in the upcoming months.2019-09-03Eventspublish
Atriva Therapeutics Receives EU Award for Biomarker ValidationAtriva Therapeutics GmbH, a biopharmaceutical company pioneering the development of host-targeting antiviral therapies, today announced that they have received the Biomarker Validation Award as part of the European Interreg Project Codex4SME.2019-07-17Press Releasepublish
Atriva Therapeutics Starts Clinical Development of novel Host-Targeting Antiviral ATR-002 Against InfluenzaAtriva Therapeutics GmbH, a biopharmaceutical company pioneering the development of host-targeting antiviral therapies, today announced the first dosing of its lead drug candidate ATR-002 in a Phase I clinical trial.2019-05-15Press Releasepublish
Atriva Therapeutics announces first closing of series A financing roundAtriva Therapeutics, a biopharmaceutical company pioneering the development of host-targeting antiviral therapies, today announced the first closing in its ongoing series A financing round lead by Meneldor and High-Tech Gründerfonds GmbH (HTGF). 2019-01-07Press Releasepublish
Wirtschaftswoche: 1,25 Mio. Euro für den Kampf gegen VirenAtriva Therapeutics GmbH, a biopharmaceutical company pioneering the development of host-targeting antiviral therapies, today announced changes to its Advisory Board.2019-01-07Media Coveragepublish
Atriva adds Dr. Christian Wallasch to its executive management team.After successfully passing an important preclinical development milestone for the lead compound ATR-002 in summer 2017, Atriva Therapeutics GmbH adds a seasoned biopharmaceutical executive, Dr. Christian Wallasch as Chief Operating Officer (COO) to its executive management team.2018-11-07Press Releasepublish
Atriva receives seed financing to develop its next generation influenza therapeuticThe next generation of Antiviral Therapies: Led by Stichting Participatie Atriva together with High-Tech Gründerfonds (HTGF), Atriva Therapeutics GmbH has received seed financing from Dutch and German private investors.2018-02-07Press Releasepublish